Despite the T cell dysregulation in AML, current immunotherapies targeting PD1, PDL1 and CTLA4 have proven insufficient to restore T cell function and have produced very limited clinical benefits30–33. This evidence concerns the gene PDCD1 and acute myeloid leukemia.